Table 1 Characteristics of study population

Subjects

30

7

6

7

 Male/female

25/5

3/4*

6/0

1/6**

Age (years)

72.3 ± 6.3

73.3 ± 6.8

75.5 ± 6.5

26.9 ± 4.0**

Smoking history

 Never/Ex- and current

7/23

3/4

0/6

6/1**

Treatment received

 None

12

0

N/A

N/A

 N-acetylcysteine

9

0

N/A

N/A

 Pirfenidone

2

0

N/A

N/A

 Steroids

3

0

N/A

N/A

 Steroids + immunosuppressant

3

5

N/A

N/A

 Steroids + Pirfenidone

1

2

N/A

N/A

Blood tests

 KL-6 (U/mL)

1174 ± 1008

951 ± 544

N/A

N/A

 SP-D (ng/mL)

240 ± 131

218 ± 215

N/A

N/A

 WBC (/μL)

7660 ± 2290

11000 ± 2290**

9270 ± 2990

N/A

 LDH (IU/L)

233 ± 58

246 ± 55

173 ± 34*

N/A

 CRP (mg/dL)

1.00 ± 2.49

2.00 ± 2.87

0.8 ± 1.08

N/A

Pulmonary function

 VC  % pred (%)

78.6 ± 23.4

75.5 ± 14.6

74.5 ± 13.9

N/A

 FVC  % pred (%)

78.4 ± 23.1

74.1 ± 16.2

70.0 ± 11.3

N/A

 FEV₁ % pred (%)

99.8 ± 28.1

86.7 ± 26.7

38.9 ± 11.7**

N/A

 FEV₁/FVC (%)

88.1 ± 6.2

80.0 ± 11.4

37.8 ± 8.1**

N/A

 DLco % pred (%)

74.9 ± 28.9

56.7 ± 19.0

94.1 ± 34.5

N/A